ArticleAmerican journal of neurodegenerative disease2025
Congenital myasthenic syndromes a rare case of AGRN mutation.
Article in American journal of neurodegenerative disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital myasthenic syndromes (CMS) are rare inherited disorders of neuromuscular transmission caused by mutations in presynaptic, synaptic, or postsynaptic components. They usually manifest in childhood with fatigability, ptosis, ophthalmoplegia, and generalized weakness, but late presentations also occur. CASE SUMMARY: We report a 20-year-old male presenting with heart failure and respiratory failure who was found to have a heterozygous AGRN gene mutation (c.4319>T; p. Pro1440Leu). Clinical features included muscle wasting, weakness, restricted gaze, and respiratory compromise requiring ICU care. Genetic sequencing confirmed AGRN-related CMS. Management included ICU support, pyridostigmine trial, heart failure therapy, salbutamol, and fluoxetine with improvement. DISCUSSION: Diagnosis of CMS requires clinical suspicion, characteristic electrophysiology, and genetic confirmation. Treatment varies with subtype; AGRN-related CMS responds variably to salbutamol and ephedrine, while cholinesterase inhibitors may be ineffective. Prognosis depends on timely diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.